ReviewCureus2026
Microneedling for Cutaneous Manifestations of Autoimmune Disease: A Scoping Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microneedling has emerged as a promising, minimally invasive modality for treating cutaneous manifestations of autoimmune diseases, including alopecia areata, vitiligo, and dermatomyositis. This procedure induces controlled microinjuries that stimulate wound healing, collagen production, and tissue remodeling, while also enhancing transdermal drug delivery. This scoping review aimed to evaluate the current evidence on the efficacy of microneedling in managing autoimmune-related dermatologic conditions. The review was conducted in accordance with the PRISMA-ScR guidelines. Peer-reviewed studies were identified through Medical Literature Analysis and Retrieval System Online (MEDLINE), Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science, a multidisciplinary citation database of scientific literature. Eligible studies were published in English between 2014 and 2024, involved adult populations, and reported original research. Review articles, non-human studies, and studies involving participants under 18 years of age were excluded. Fourteen studies met the inclusion criteria. Overall, microneedling demonstrated benefit primarily as an adjunctive therapy, with improved outcomes reported when combined with treatments such as corticosteroids, platelet-rich plasma, and narrowband ultraviolet B therapy. Evidence supports its role in promoting hair regrowth in alopecia areata and facilitating repigmentation in vitiligo. Limited evidence from a case report suggests potential benefit in reducing calcinosis cutis in dermatomyositis. The therapeutic effects of microneedling appear to be mediated by enhanced drug absorption and stimulation of local regenerative pathways. Although findings are promising, the current evidence is limited by small sample sizes, heterogeneity in study design, and short follow-up periods. Larger, well-designed randomized controlled trials are needed to establish standardized treatment protocols and to better assess long-term safety and efficacy. Microneedling represents a potential adjunctive treatment option for autoimmune-related cutaneous conditions and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.